White Paper

Parenteral packaging’s pivotal role in patient safety

Parenteral drugs are administered by injection or infusion rather than through the gastrointestinal tract. The performance of primary packaging components—including stoppers, plungers and closures—can therefore directly affect drug quality and patient safety.
Container closure integrity (CCI) is a fundamental packaging requirement, but the appropriate system depends on the application. Multi-dose vials, sensitive biologics and home-use injection devices can present different performance requirements.
Quality must be designed into component manufacturing from the outset. Controls such as ISO 5 cleanroom environments, automated inspection and fluoropolymer-coated components can help reduce contamination, defects and drug–packaging interactions.

Status Published

Format White Paper

Language English

Access Registration Required

Access the White Paper Talk to a Packaging Expert

Resource Overview

What is parenteral packaging?

Parenteral packaging refers here to the primary container-closure systems used to store and deliver injectable drug products. Common routes of administration include:

Intravenous
Subcutaneous
Intramuscular
Intradermal

These systems encompass a range of precision-engineered components including vial stoppers, syringe plungers, prefilled syringe closures, and cartridges. Each one of these components is a critical interface between a drug formulation and the patient it is designed to treat.

Container closure integrity (CCI) is the overriding patient safety priority in parenteral packaging — failures can lead to drug degradation, incorrect dosing, or direct contamination of a patient's bloodstream, with consequences that are especially severe for self-administered biologics in home care settings.
Extractables and leachables (E&L) from elastomeric closures pose a direct risk to sensitive biologic drugs, potentially causing protein denaturation, loss of efficacy, or adverse patient reactions — making elastomer compound selection and coating strategy critical decisions in packaging development.
Datwyler's FirstLine® manufacturing standard — featuring ISO 5 cleanrooms, 100% automated camera and metal detection inspection, paperless production, and fluoropolymer-coated OmniFlex® and NeoFlex™ components — is purpose-built to deliver the lowest achievable contamination and defect levels for high-risk injectable drug applications.

Why is parenteral packaging critical for patient safety?

Unlike oral medications, injectable drugs bypass the gastrointestinal tract and some of the body’s protective barriers. The performance of every component in the delivery system can therefore affect drug quality and patient safety.

This is especially important in home-care drug delivery, where injectable systems must perform reliably outside controlled clinical environments and in the hands of patients or caregivers.

Primary packaging plays a critical role in protecting the drug product throughout manufacturing, storage, transportation and final delivery.

The shift toward home-care drug delivery

The importance of primary packaging has grown as the market moves toward home-care solutions. Prefilled syringes and autoinjectors can give patients greater autonomy over medication administration, while requiring packaging systems that maintain integrity during everyday handling, transportation and use outside controlled healthcare facilities.

This is particularly relevant for treatments such as insulin, where patients may administer multiple injections and carry their drug delivery devices with them. Packaging components must continue to perform reliably throughout the product’s intended use.

Container closure integrity in parenteral packaging

At the heart of parenteral packaging performance is container closure integrity, or CCI. CCI refers to a container-closure system’s ability to maintain its seal and sterile barrier throughout its intended shelf life and use. This helps prevent environmental ingress, contamination and product loss.

A compromised seal can affect sterility, product quality or dose delivery and may render a product ineffective or unsafe.

CCI requirements are application-specific. A multi-dose vial that is punctured repeatedly requires a closure that reseals reliably after each use. A home-use drug delivery device may be carried in a pocket or bag, requiring its container-closure system to withstand movement and impacts without compromising integrity.

Each application brings different requirements. Packaging teams must therefore select components and systems that meet the needs of the drug product, delivery device and intended use.

Patient safety risks associated with parenteral packaging

The white paper examines patient safety risks associated with parenteral packaging, including:

Container closure integrity failures
Extractables and leachables interactions with sensitive biologics
Visible and sub-visible particulate contamination
Self-sealing performance of multi-dose elastomeric closures

By applying appropriate risk-management, design and manufacturing controls, packaging teams can mitigate these risks throughout development and production.

Manufacturing excellence in parenteral packaging

Addressing the risks associated with parenteral packaging requires a manufacturing philosophy built around patient safety. For Datwyler, this means applying quality-by-design principles so that protection is engineered into components and processes from the outset.

FirstLine® manufacturing

Datwyler’s FirstLine® manufacturing standard combines ISO 5 cleanroom environments, automated production cells and 100% automated camera inspection to help identify defects before a component reaches a drug product.

Operating under a zero-defect philosophy, FirstLine® minimises human contact with the manufacturing environment. It is particularly well suited to sensitive biologics and orphan drugs, where component quality and cleanliness are critical.

Fluoropolymer coating technology

Datwyler’s OmniFlex® stoppers and NeoFlex™ plungers feature a full-surface fluoropolymer spray coating that creates a protective barrier between the elastomer and the drug product.

This coating is designed to reduce the potential for extractables and leachables to interact with sensitive formulations while supporting component cleanliness and drug compatibility.

To learn more about how Datwyler’s approach helps protect drug integrity across the parenteral packaging supply chain, download the full white paper.

Parenteral packaging’s pivotal role in patient safety

What is parenteral packaging?